We are 3-Iodotoluene CAS:625-95-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests
Related News: With the onset of the DMF system for APIs, the concentration of the API industry will further increase.5-(3-methylbut-2-enoxy)-5-oxo-2-[2-(phenylmethoxycarbonylamino)-1,3-thiazol-4-yl]pent-2-enoic acid The company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments.3H-1,3,4-thiadiazole-2-thione CAS:18686-82-3 Beneficial drug raw materials refer to the active pharmaceutical ingredients used in the manufacture of original research drugs (patent drugs). They are mainly used to meet the needs of original multinational pharmaceutical companies and emerging biopharmaceutical companies for innovative drugs in clinical drug research, registration approval and commercialization sales , Which also contains advanced intermediates used in the manufacture of the drug substance that need to be regulated by regulatory authorities.2-desoxi-2,2-difluoro-D-eritro-pentofuranosa-3,5-dibenzoato-1-metanosulfonato CAS:122111-11-9 Beneficial drug raw materials refer to the active pharmaceutical ingredients used in the manufacture of original research drugs (patent drugs). They are mainly used to meet the needs of original multinational pharmaceutical companies and emerging biopharmaceutical companies for innovative drugs in clinical drug research, registration approval and commercialization sales , Which also contains advanced intermediates used in the manufacture of the drug substance that need to be regulated by regulatory authorities.The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.
Product Name | |
---|---|
uridine diphosphate rhamnose Cas:1955-26-6 | View Details |
4-chloro-2,6-diphenylpyrimidine | View Details |
HYDROQUINONE Cas:123-31-9 | View Details |